China grants world's first commercial approval for brain implant

China’s Neuracle Medical Technology (NMT) has become the first company in the world to receive commercial regulatory approval for a plantable brain-computer interface (BCI) system. Designed to restore motor function in patients with spinal cord injuries, the wireless device is implanted on the brain cortex without penetrating brain tissue, reducing damage risk. It reads neural signals related to movement and converts them into commands to control robotic or prosthetic limbs. This approval marks a significant milestone, transitioning BCIs from experimental research tools to prescribable medical devices, potentially comparable to pacemakers in clinical use. The development reflects China’s strategic push to lead in advanced technologies such as BCIs, artificial intelligence, quantum computing, and biotechnology. By fast-tracking approvals and supporting companies like NMT, China aims to compete with foreign rivals like Elon Musk’s Neuralink. Beyond motor function restoration, BCIs hold promise for treating conditions like ALS, stroke, epilepsy, and Parkinson’s, as well as future applications in speech